Jinglin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinglin Xu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Chunyan Fu
Department of Neonatology, Quanzhou Maternity and Children’s Hospital, Quanzhou, China
2 shared publicationsDongmei Chen
Department of Neonatology, Quanzhou Maternity and Children’s Hospital, Quanzhou, China
2 shared publications- Dongmei Chen
Department of Neonatology, Quanzhou Maternal and Child Health Hospital, Quanzhou, China
2 shared publications He Wang
Department of Neonatology, Quanzhou Maternity and Children’s Hospital, Quanzhou, China
2 shared publicationsHongyuan Yang
Department of Neonatology, Quanzhou Maternity and Children’s Hospital, Quanzhou, China
2 shared publicationsRuiquan Wang
2 shared publications
Latest Publications
- 29 August 2026
- Published by Springer Nature in Pediatric Research
- p. 1-11
Bifidobacterium modulates gut microbiota and aryl hydrocarbon receptor signaling in necrotizing enterocolitis rat model
Background Neonatal necrotizing enterocolitis (NEC) is linked to gut microbiota dysbiosis and inflammation. Bifidobacterium-mediated tryptophan metabolites, including indole-3-lactic acid (ILA), may exert anti-inflammatory effects via the aryl hydrocarbon receptor (AhR) pathway. This study investigated the protective effects and mechanisms of Bifidobacterium BB-12 in NEC. Methods Neonatal rats were assigned to a control, NEC, and Bifidobacterium-treated NEC groups. Clinical symptoms, survival, serum cytokines, intestinal pathology, microbiota structure (16S rRNA sequencing), and AhR/CYP1A1 expression (quantitative reverse transcription polymerase chain reaction, western blotting) were evaluated. Colon metabolomics and in vitro lipopolysaccharide (LPS)-induced intestinal epithelial cell assays with AhR knockdown were performed to assess the role of ILA. Results Bifidobacterium markedly alleviated symptoms, reduced intestinal damage, increased survival, and suppressed inflammatory factors. It restored gut microbiota diversity by increasing beneficial taxa (Bacteroidetes, Actinobacteria, Bifidobacterium), and decreasing pathogenic bacteria (Proteobacteria, Shigella-Escherichia). AhR/CYP1A1 expression was upregulated and negatively correlated with tissue damage. Metabolomics revealed elevated levels of ILA, indole-3-aldehyde, and 3-hydroxyanthranilic acid. In vitro, ILA inhibited LPS-induced inflammation and upregulated AhR/CYP1A1, while AhR knockdown largely abolished these effects. Conclusion Bifidobacterium BB-12 protects against NEC by reshaping the gut microbiota, activating the AhR-CYP1A1 pathway, and regulating tryptophan metabolites, with ILA partially mediating its anti-inflammatory effects. Impact Neonatal necrotizing enterocolitis is a severe inflammatory bowel disease in premature infants with limited treatment options, highlighting the need for new preventive and therapeutic strategies. Bifidobacterium is an effective probiotic, but its molecular mechanisms in NEC through host metabolic-immune interactions remain unclear. This study strongly suggest that in a neonatal rat NEC model, Bifidobacterium alleviates intestinal inflammation and tissue damage by reshaping the gut microbiota, elevating tryptophan metabolites like ILA, and activating the AhR-CYP1A1 signaling pathway. The findings provide a framework for understanding probiotic-mediated gut protection and potential targets for interventions using microbial metabolites or AhR agonists.
- 29 August 2026
- Published by Springer Nature in Pediatric Research
- p. 1-11
Bifidobacterium modulates gut microbiota and aryl hydrocarbon receptor signaling in necrotizing enterocolitis rat model
Background Neonatal necrotizing enterocolitis (NEC) is linked to gut microbiota dysbiosis and inflammation. Bifidobacterium-mediated tryptophan metabolites, including indole-3-lactic acid (ILA), may exert anti-inflammatory effects via the aryl hydrocarbon receptor (AhR) pathway. This study investigated the protective effects and mechanisms of Bifidobacterium BB-12 in NEC. Methods Neonatal rats were assigned to a control, NEC, and Bifidobacterium-treated NEC groups. Clinical symptoms, survival, serum cytokines, intestinal pathology, microbiota structure (16S rRNA sequencing), and AhR/CYP1A1 expression (quantitative reverse transcription polymerase chain reaction, western blotting) were evaluated. Colon metabolomics and in vitro lipopolysaccharide (LPS)-induced intestinal epithelial cell assays with AhR knockdown were performed to assess the role of ILA. Results Bifidobacterium markedly alleviated symptoms, reduced intestinal damage, increased survival, and suppressed inflammatory factors. It restored gut microbiota diversity by increasing beneficial taxa (Bacteroidetes, Actinobacteria, Bifidobacterium), and decreasing pathogenic bacteria (Proteobacteria, Shigella-Escherichia). AhR/CYP1A1 expression was upregulated and negatively correlated with tissue damage. Metabolomics revealed elevated levels of ILA, indole-3-aldehyde, and 3-hydroxyanthranilic acid. In vitro, ILA inhibited LPS-induced inflammation and upregulated AhR/CYP1A1, while AhR knockdown largely abolished these effects. Conclusion Bifidobacterium BB-12 protects against NEC by reshaping the gut microbiota, activating the AhR-CYP1A1 pathway, and regulating tryptophan metabolites, with ILA partially mediating its anti-inflammatory effects. Impact Neonatal necrotizing enterocolitis is a severe inflammatory bowel disease in premature infants with limited treatment options, highlighting the need for new preventive and therapeutic strategies. Bifidobacterium is an effective probiotic, but its molecular mechanisms in NEC through host metabolic-immune interactions remain unclear. This study strongly suggest that in a neonatal rat NEC model, Bifidobacterium alleviates intestinal inflammation and tissue damage by reshaping the gut microbiota, elevating tryptophan metabolites like ILA, and activating the AhR-CYP1A1 signaling pathway. The findings provide a framework for understanding probiotic-mediated gut protection and potential targets for interventions using microbial metabolites or AhR agonists.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 43
Genetic spectrum of unexplained neonatal seizures: a single-center study
Up to 40% of neonatal seizures remain unexplained after standard evaluation, creating a diagnostic imperative. Distinguishing genetic etiologies is critical, as it enables the identification of treatable conditions and informs prognosis and family counseling. In this study, we aimed to define the genetic spectrum of unexplained neonatal seizures in a Chinese cohort. In this single-center retrospective case series, we enrolled 40 neonates [2016–2024] admitted to the neonatal intensive care unit with video electroencephalography (vEEG)-confirmed seizures that were “unexplained” after a comprehensive evaluation including neuroimaging and metabolic screening. Exclusion criteria included identified causes such as hypoxic-ischemic encephalopathy or confirmed metabolic disorders. Genetic analysis involved whole-exome sequencing (WES), clinical exome sequencing (CES), WES of patient and parents (trio) (trio-WES), and mitochondrial DNA analysis. The cohort included 29 male and 11 female neonates, with a median seizure onset at 1.5 days of life. Pathogenic or likely pathogenic variants were detected in 67.5% (27/40) of cases, including, but not limited to, variants in KCNQ2, ALDH7A1, and SUOX. A dual diagnosis was identified in one individual with compound heterozygous SUOX mutations and a de novo TUBG1 deletion. Additionally, nine of the 28 identified variants were novel. Although diagnostic yields varied among methodologies, the differences were not significant. Three patients with ALDH7A1 mutations achieved seizure freedom with vitamin B6 alone. All patients with SUOX nonsense/frameshift mutations had severe phenotypes and poor outcomes. Our findings demonstrate a high diagnostic yield of next-generation sequencing (NGS) in unexplained neonatal seizures and underscore its clinical utility in pinpointing treatable conditions and prognosticating severe disorders.
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 43
Open AccessGenetic spectrum of unexplained neonatal seizures: a single-center study
Up to 40% of neonatal seizures remain unexplained after standard evaluation, creating a diagnostic imperative. Distinguishing genetic etiologies is critical, as it enables the identification of treatable conditions and informs prognosis and family counseling. In this study, we aimed to define the genetic spectrum of unexplained neonatal seizures in a Chinese cohort. In this single-center retrospective case series, we enrolled 40 neonates [2016–2024] admitted to the neonatal intensive care unit with video electroencephalography (vEEG)-confirmed seizures that were “unexplained” after a comprehensive evaluation including neuroimaging and metabolic screening. Exclusion criteria included identified causes such as hypoxic-ischemic encephalopathy or confirmed metabolic disorders. Genetic analysis involved whole-exome sequencing (WES), clinical exome sequencing (CES), WES of patient and parents (trio) (trio-WES), and mitochondrial DNA analysis. The cohort included 29 male and 11 female neonates, with a median seizure onset at 1.5 days of life. Pathogenic or likely pathogenic variants were detected in 67.5% (27/40) of cases, including, but not limited to, variants in KCNQ2, ALDH7A1, and SUOX. A dual diagnosis was identified in one individual with compound heterozygous SUOX mutations and a de novo TUBG1 deletion. Additionally, nine of the 28 identified variants were novel. Although diagnostic yields varied among methodologies, the differences were not significant. Three patients with ALDH7A1 mutations achieved seizure freedom with vitamin B6 alone. All patients with SUOX nonsense/frameshift mutations had severe phenotypes and poor outcomes. Our findings demonstrate a high diagnostic yield of next-generation sequencing (NGS) in unexplained neonatal seizures and underscore its clinical utility in pinpointing treatable conditions and prognosticating severe disorders.
- 13 September 2024
- Published by Springer Nature in Pediatric Research
- Vol. 97 (3) , 1171-1182
Bifidobacterium regulates premature infant gut metabolites, reducing serum inflammatory factors: a randomised controlled trial
Background Analyse the effects of Bifidobacterium BB-12 on intestinal metabolites and serum inflammatory factors in premature infants. Methods 71 premature infants at gestational age of ≤32 weeks were randomly divided into the probiotic (n = 36) and control (n = 35) groups. Faecal and blood samples were collected from the two groups of premature infants at the 2nd and 4th week of life for intestinal metabolite detection and assessment of the level of the serum inflammatory markers TLR4, NF- κ B, IL-1β, and TNF- α. Results Compared to the control group, the probiotic group contained more amino acids, these elements were enriched on multiple amino acid metabolic pathways, and the probiotic group showed significantly lower levels of the serum inflammatory markers TLR4, NF-κB, IL-1β, and TNF-α. Finally, the probiotic group showed a lower incidence of feeding intolerance. Conclusions The administration of Bifidobacterium BB-12 is associated with increasing the levels of glutamine, glutamic acid, and kynurenine in the gut of premature infants, and associated with reducing the levels of TLR4 and NF-κB in the serum, further decreasing the secretion of the pro-inflammatory factors IL-1β and TNF-α, and alleviating systemic inflammatory reactions, thereby reducing the incidence of feeding intolerance. Impact 1. The use of Bifidobacterium BB-12 in premature infants can increase the levels of amino acids in the intestine. 2. Increases in Bifidobacterium BB-12 may decrease the serum levels of TLR4, NF-κB, IL-1β, and TNF-α. 3. Kynurenine may improve the prognosis of preterm infants by reducing inflammation. 4. Bifidobacterium BB-12 may improve the feeding tolerance of premature infants, thus reducing the incidence of feeding intolerance.
- 13 September 2024
- Published by Springer Nature in Pediatric Research
- Vol. 97 (3) , 1171-1182
Bifidobacterium regulates premature infant gut metabolites, reducing serum inflammatory factors: a randomised controlled trial
Background Analyse the effects of Bifidobacterium BB-12 on intestinal metabolites and serum inflammatory factors in premature infants. Methods 71 premature infants at gestational age of ≤32 weeks were randomly divided into the probiotic (n = 36) and control (n = 35) groups. Faecal and blood samples were collected from the two groups of premature infants at the 2nd and 4th week of life for intestinal metabolite detection and assessment of the level of the serum inflammatory markers TLR4, NF- κ B, IL-1β, and TNF- α. Results Compared to the control group, the probiotic group contained more amino acids, these elements were enriched on multiple amino acid metabolic pathways, and the probiotic group showed significantly lower levels of the serum inflammatory markers TLR4, NF-κB, IL-1β, and TNF-α. Finally, the probiotic group showed a lower incidence of feeding intolerance. Conclusions The administration of Bifidobacterium BB-12 is associated with increasing the levels of glutamine, glutamic acid, and kynurenine in the gut of premature infants, and associated with reducing the levels of TLR4 and NF-κB in the serum, further decreasing the secretion of the pro-inflammatory factors IL-1β and TNF-α, and alleviating systemic inflammatory reactions, thereby reducing the incidence of feeding intolerance. Impact 1. The use of Bifidobacterium BB-12 in premature infants can increase the levels of amino acids in the intestine. 2. Increases in Bifidobacterium BB-12 may decrease the serum levels of TLR4, NF-κB, IL-1β, and TNF-α. 3. Kynurenine may improve the prognosis of preterm infants by reducing inflammation. 4. Bifidobacterium BB-12 may improve the feeding tolerance of premature infants, thus reducing the incidence of feeding intolerance.